Adoptive cellular immunotherapy for EBV lymphoproliferative diseases

Immunological Reviews

Volumn 157, Issue , 1997, Pages 217-222

  Heslop, Helen E ^a,b   Rooney, Cliona M ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; REVIEW; VIRUS IMMUNITY; VIRUS REACTIVATION;

HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOPROLIFERATIVE DISORDERS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0030810431     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1997.tb00984.x     Document Type: Review

References (39)

1. Rickinson AB, Lee SP, Steven NM. Cytotoxic T lymphocyte responses to Epstein-Barr virus. Curr Opin Immunol 1996;8:492-497.
2. Klein G. Epstein-Barr virus strategy in normal and neoplastic B cells. Cell 1994;77:791-793.
3. Bourgault I, Gomez A, Gomard E, Levy JP. Limiting-dilution analysis of the HLA restriction of anti-Epstein-Barr virus-specific cytolytic T lymphocytes. Clin Exp Immunol 1991;84:501-507.
4. Lucas K, Small T, Heller G, Dupont B, O'Reilly RJ. The development of cellular immunity to Epstein-Barr virus after allogeneic hone marrow transplantation. Blood 1996;87:2594-2603.
5. Cohen KI. Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency. Proc Natl Acad Sci USA 1991;86:9558-9561.
6. Straus SE, Cohen JI, Tosato G, Meier J. Epstein-Barr virus infections: biology, pathogenesis and management. Ann Intern Med 1992;118:45-58.
7. Rickinson AB, Kieff E. Epstein-Barr Virus. In: Fields BN, Knipe DM, Howley PM, eds. Field's virology. Philadelphia: Lipincott-Raven; 1996. p.2397-2446.
8. Anasetti C, Etzioni R, Petersdorf EW, Martin PJ, Hansen JA. Marrow transplantation from unrelated volunteer donors. Annu Rev Med 1995;46:169-179.
9. Marks DI, et al. Allogeneic hone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors: a comparison of complications in the first two years. Ann Intern Med 1993;119:207-214.
10. Cela ME, et al. Gamma delta T lymphocyte regeneration after T lymphocyte-depleted bone marrow transplantation from mismatched family members or matched unrelated donors. Bone Marrow Transplant 1996;17:243-247.
11. Caldas C, Ambinder R. Epstein-Barr virus and bone marrow transplantation. Curr Opin Oncol 1995;7:102-106.
12. Skinner JC, et al. B cell lymphoproliferative disorders following T cell depleted allogeneic bone marrow transplantation. Am J Ped Hematol/Oncol 1988;10:112-119.
13. Shapiro RS, et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988;71:1234-1243.
14. Zutter MM, et al. Epstein-Barr virus lymphoproliferation alter bone marrow transplantation. Blood 1988;72:520-529.
15. Papadopoulos EB, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994;330:1185-1191.
16. Heslop HE, Brenner MK, Rooney CM. Donor T cells to treat EBV-associated lymphoma. N Engl J Med 1994;331:679-680.
17. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992;257:238-241.
18. Walter EA, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333:1038-1044.
19. Murray RJ, et al. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med 1992;176:157-168.
20. Khanna R, et al. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia; implications for vaccine development. J Exp Med 1992;176:169-176.
21. Heslop HE, et al. Administration of neomycin resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts. Hum Gene Ther 1994;5:381-397.
22. + cytotoxic T cell responses during chronic viral infection. J Virol 1994;68:8056-8063.
23. Smith CA, et al. Production of genetically modified EBV specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J Hematother 1995;4:73-79.
24. Smith CA, et al. Adoptive immunotherapy for Epstein-Barr virus-related lymphoma. Leuk Lymphoma 1996;23:213-220.
25. Rooney CM, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 1995;345:9-13.
26. Burrows SR, Khanna R, Burrows JM, Moss DJ. An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft-versus-host disease. J Exp Med 1994;179:1155-1161.
27. Heslop HE, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996;2:551-555.
28. Rooney CM, Loftin SK, Holladay MS, Brenner MK, Krance RA, Heslop HE. Early identification of Epstein-Barr virus-associated post-transplant lymphoproliferative disease. Br J Haematol 1995;89:98-103.
29. Savoie A, Perpete C, Carpentier L, Joncas J, Alfieri C. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood 1994;83:2715-2722.
30. Riddler SA, Breinig MC, McKnight JLC. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood 1994,84:972-984.
31. Romani N, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994;180:83-93.
32. Roskrow MA, Suzuki N, Brenner MK, Rooney CM. Genetically modified dendritic cells generate primary and memory tumor antigen-specific cytotoxic T lymphocytes. Blood 1996;10(Suppl 1):87 (Abstract).
33. Tiberghien R et al. Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation? Blood 1994;84:1333-1341.
34. Mavilio F, et al. Peripheral blood lymphocytes as target cells of retroviral vector-mediated gene- transfer. Blood 1994;83:1988-1997.
35. Riddell SR, et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 1996;2:216-223.
36. Bonini C, et al. A pilot study of HSV-TK gene transfer into donor peripheral blood lymphocytes for controlled GVL after allo-BMT. Blood 1996;88(Suppl 1):10 (Abstract).
37. Smith CA, Woodruff LS, Kitchingman GR, Rooney CM. Adenovirus-pulsed dendritic cells stimulate human virus-specific T-cell responses in vitro. J Virol 1996;70:6733-6740.
38. Roskrow MA, Suzuki N, Heslop HE, Hudson M, Brenner MK, Rooney CM. Genetically modified EBV-specific cytotoxic T cells for adoptive transfer to patients with EBV-positive Hodgkin disease. Blood 1996;88(Suppl 1):673 (Abstract).
39. Levitskaya J, et al. Inhibition of antigen processing by the internal repeat region oi the Epstein-Barr virus nuclear antigen-1. Nature 1995;375:685-688.